Track topics on Twitter Track topics that are important to you
How is Ibrance faring? Is Kisqali expected to be a threat?
Having dominated the HER2positive breast cancer space for many years, Roche's blockbuster drug Herceptin is likely to face the threat of biosimilar trastuzumab in the coming years; KOLs weigh in on how biosimilar trastuzumab may be accepted by physicians and patients, its potential usage in different settings, as well as its chances to become the preferred agent in the HER2positive space. Meanwhile, KOLs discuss how Roche's Perjeta is setting itself up for expanded use. Experts also give their views on how Pfizer's Ibrance is faring in the HER2negative/HRpositive space and what challenges lie ahead for this drug, including the arrival of Novartis' Kisqali and Eli Lilly's abemaciclib. The potential usage of PARP inhibitors and PD1/PDL1 checkpoint inhibitors in triplenegative breast cancer is also explored. Twelve US and EU KOLs offer their candid insights on these issues and more.
In this 6 US and six EU KOLs offer their candid insights on 6 marketed therapies and 12 pipeline drugs.
Take a tour of the report now:
Alpelisib is clearly more selective or alpha specific. This should allow for better targeting but we'll see if that pans out clinically. I think we need to be careful with the toxicity of these drugs.EU Key Opinion Leader
There are still studies that need to be completed to address the issue of sequencing of different therapies. The bulk of the evidence does support firstline use with a CDK4/6 inhibitor, but then after you get beyond firstline therapy, it starts to become a bit more confusing. US Key Opinion Leader
Sample of therapies covered
Sample of KOLs interviewed
KOLs from North America
KOLs from Europe
Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...